London, Feb 16, 2026, 08:20 GMT — Regular session
- GSK picked up roughly 0.4% early, sticking close to its recent peak.
- After this month’s results, attention turns to the Feb. 19 ex-dividend date.
- Traders are tracking vaccine momentum and any deal-making hints with the new CEO in place.
GSK plc opened higher in London on Monday, ticking up about 0.4% to 2,173 pence in early moves. Shares changed hands between 2,153 and 2,173 pence, following a previous close of 2,165. (Investing)
GSK has already rallied hard, so now the calendar’s taking over from headlines. With the week kicking off light on new company news, investors usually pivot to whatever’s on the schedule—anything they can anticipate and actually trade.
For GSK, the immediate focus is the dividend threshold. Shares tend to meander as income funds settle in, and some traders keep their distance to sidestep the usual “ex-dividend” markdown—a price move tied to the coming cash distribution.
GSK posted its full-year numbers earlier this month, sticking to its 2026 forecast. The drugmaker said turnover should rise between 3% and 5%, with core operating profit and core EPS climbing 7% to 9%. “Core” is GSK’s adjusted metric, which excludes certain one-off items. (Gsk)
That day, new CEO Luke Miels said the company has to “accelerate what we have” and pursue “smart business development” to bring in more assets. Quilter Cheviot healthcare analyst Sheena Berry described the outlook as a “steady and credible start” for Miels. (Reuters)
Last week, investors got another piece of vaccine news to digest: GSK announced that Chinese regulators have accepted its application for Arexvy, the RSV vaccine targeting adults 60 and up. (Gsk)
Still, there’s a catch. Should vaccine demand fade more quickly than anticipated later in the quarter, or pricing pressure returns in major markets, that recent bump in the shares could end up looking overdone.
Traders have their eyes on GSK to see if the “bolt-on” deal chatter turns into real action. Sure, smaller buys could offer a lift, though they also raise fresh concerns about valuation discipline, especially given the stock’s already stretched price compared to its own track record.
Coming up, GSK’s ex-dividend date for its Q4 2025 ordinary shares lands on Feb. 19, with the payout scheduled for April 9. Mark another date: April 29 is when the company will release its next set of results. (Gsk)
